FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1861-1862 November 1, 2007 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

More than 300,000 hip fractures occur annually in the United States,¹ the majority related to osteoporosis and falls in older people. Not surprisingly, the public health implications and economic burden associated with this condition are enormous.^2,3 In patients who have sustained a hip fracture, a 2-year mortality rate of 36% has been observed.⁴ Many of those who survive do not regain their prefracture level of mobility⁵ and thereby endure loss of independence and deterioration in health-related quality of life. Persons who fracture a hip are 2.5 times as likely to have a subsequent skeletal fracture as are those without a . . . [Full Text of this Article]

Source Information

From the Department of Pharmacy, Mark O. Hatfield Clinical Research Center, National Institutes of Health, Bethesda (K.A.C., F.P.); the Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland, Baltimore (K.A.C.); and the Endocrinology Expert Committee, United States Pharmacopeia, Rockville (K.A.C., F.P.) — all in Maryland.

This article (10.1056/NEJMe078192) was published at www.nejm.org on September 17, 2007.

This article has been cited by other articles:

• Visekruna, M., Wilson, D., McKiernan, F. E. (2008). Severely Suppressed Bone Turnover and Atypical Skeletal Fragility. J. Clin. Endocrinol. Metab. 93: 2948-2952 [Abstract] [Full Text]  
• van den Berg, P., Lopez, C. A., Tasneem, Z., Karam, R., Al-Khalidi, H., Steinbuch, M., Colon-Emeric, C. S., Lyles, K. W., Mesenbrink, P., the HORIZON Recurrent Fracture Trial, (2008). Zoledronate, fractures, and mortality after hip fracture.. NEJM 358: 967-968 [Full Text]